B2B
The company developing Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV).
myr-pharma.com
Location: Germany, Hesse, Bad Homburg vor der Höhe
Total raised: $711.09K
Investors 2
| Date | Name | Website |
| - | Joint Jour... | jj.capital |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2011 | - | $711.09K | High-Tech ... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 04.11.2014 | MYR Raises $10M | MYR GmbH, a Burgwedel, Germany-based biotechnology company, raised $10m in funding. Backers include... | finsmes.co... |
| 12.05.2011 | MYR Receives €500K Equity Investment from High-Tech Gründerf... | MYR GmbH, a Burgwedel (Hannover), Germany-based biotech company that develops a drug for the treatme... | finsmes.co... |
| - | Most Successful Exit in the History of High-Tech Gründerfond... | December 10, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH (MYR) announced that the compan... | htgf.de/en... |